ADC Therapeutics SA at Jefferies London Healthcare Conference Transcript
Good morning everyone, thank you for attending Jeffries London Healthcare Conference my name is Kelly Shi, one of the biotech analyst here at Jeffries. Please join me on. Welcome Mr. Ameet Mallik, CEO of ADC Therapeutics for this fireside chat session. Welcome.
Thank you
Questions & Answers
And ADC's space has been very active in making promising clinical progresses and the BD transactions. How does this recent trends in the ADC space, this impact your long-term strategy with your technology platform?
Yeah. Thank you. Kelly. So as you know, ADC Therapeutics is a commercial stage company but also with a very rich platform as well. We already have a product on the approved in the market with Zynlonta and we've been focusing up to this point largely on PBD-based payloads. But if you look at the next generation of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
